Fall 2025
Posted on 3/18/2025
Develops tubeless insulin delivery systems
$23 - $27.50/hr
San Diego, CA, USA
Get referrals →
You have ways to get a Insulet Corporation referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 6 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Insulet Corporation focuses on creating medical devices that make life easier for individuals with diabetes and other health conditions. Their main product, the Omnipod Insulin Management System, offers a different approach to insulin delivery compared to traditional methods. The Omnipod is a tubeless, disposable device that can deliver insulin continuously for up to three days without the need for needles. A key feature of the Omnipod 5 Automated Insulin Delivery System is its ability to work with a continuous glucose monitor, allowing users to manage their blood sugar levels without daily injections or fingersticks. This system can be controlled via a smartphone or a dedicated controller. Insulet stands out from competitors by providing a simple, wearable solution that eliminates the hassle of traditional insulin delivery methods. The company's goal is to improve the quality of life for people with diabetes by offering convenient and effective insulin management solutions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Acton, Massachusetts
Founded
2000
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Insulet Corp. (PODD), a medical device company, on Monday announced that Chief Executive Officer Jim Hollingshead has resigned from the Board of Directors.
Ashley McEvoy has been tapped to be president and CEO of Insulet.
Insulet competes with companies like DexCom, Tandem Diabetes Care, and Masimo Corporation in the diabetes care market.
Insulet raises $444.4M through senior notes to refinance existing convertible debt. Strategic move positions medical device maker for future growth while optimizing capital structure.
Insulet (NASDAQ: PODD) will present results from its multinational RADIANT trial at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2025.